Stay updated with breaking news from Aurora Kinase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The AURKA inhibitor alisertib has emerged as an agent of particular note, demonstrating early signals of efficacy with a manageable safety profile for the treatment of patients with locally advanced or metastatic breast cancer whose disease is resistant to endocrine therapies.
Puma Biotechnology, Inc. announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the treatment of patients with Rb-deficient head and neck squamous cell carcinoma...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the treatment of patients with Rb-deficient head...
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the treatment of patients with Rb-deficient head and neck squamous cell carcinoma (Clinicaltrials.gov identifier NCT04555837)...